Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Work In Process (2023 - 2025)

Historic Work In Process for Tg Therapeutics (TGTX) over the last 3 years, with Q3 2025 value amounting to $121.8 million.

  • Tg Therapeutics' Work In Process rose 6246.65% to $121.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.8 million, marking a year-over-year increase of 6246.65%. This contributed to the annual value of $68.4 million for FY2024, which is 11883.68% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Work In Process is $121.8 million, which was up 6246.65% from $129.2 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Work In Process registered a high of $142.9 million during Q1 2025, and its lowest value of $27.1 million during Q1 2023.
  • In the last 3 years, Tg Therapeutics' Work In Process had a median value of $74.1 million in 2024 and averaged $73.5 million.
  • Per our database at Business Quant, Tg Therapeutics' Work In Process soared by 17299.32% in 2024 and then soared by 6246.65% in 2025.
  • Tg Therapeutics' Work In Process (Quarter) stood at $31.2 million in 2023, then surged by 118.84% to $68.4 million in 2024, then surged by 78.16% to $121.8 million in 2025.
  • Its Work In Process stands at $121.8 million for Q3 2025, versus $129.2 million for Q2 2025 and $142.9 million for Q1 2025.